Loading...
Market
Will Wave Life Sciences complete Phase 3 trials of WVE-006 for AATD by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Wave Life Sciences' official press releases or clinical trial registries
Story
Wave Life Sciences Achieves First-Ever Therapeutic RNA Editing in Humans, Stock Surges 55%
Oct 16, 2024, 02:44 PM
Wave Life Sciences announced a groundbreaking achievement in the field of RNA editing with their RestorAATion-2 trial of WVE-006. The trial, which targets Alpha-1 Antitrypsin Deficiency (AATD), demonstrated the first-ever therapeutic RNA editing in humans. A single subcutaneous dose of WVE-006 in the first two patients resulted in mean plasma total AAT levels of approximately 11 micromolar, with a mean wild-type M-AAT protein increase to 6%. This milestone has led to a significant surge in Wave Life Sciences' stock, which rose by 55%. The achievement is seen as a major de-risking of the new modality and has potential implications for other companies in the RNA editing space, including PRQR and KRRO. Wave Life Sciences will host a Virtual R&D day on October 30th to discuss this breakthrough, which is the result of over 10 years of oligonucleotide innovation.
View original story
Similar markets
Yes • 50%
No • 50%
Phase 3 trial initiation • 25%
FDA breakthrough therapy designation • 25%
Partnership with a major pharma • 25%
Other milestone • 25%
Huntington's Disease • 25%
ALS • 25%
Duchenne Muscular Dystrophy • 25%
Other • 25%
Neurological Disorders • 25%
Genetic Diseases • 25%
Oncology • 25%
Other • 25%
Yes • 50%
No • 50%